ArticleEuropean journal of nuclear medicine and molecular imaging2024
Clinical translation of a novel FAPI dimer [
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07128277 (Clinical Study of Trap), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of Trap (FAPI) 3 PET Imaging in Noninvasive Diagnosis of Malignant Tumors
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Preclinical evaluation of homodimeric FAPI target modules for UniCAR-mediated targeting of FAP-expressing tumor and stromal cells.Oncoimmunology · 2026Article
- Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.GluEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Dual-Target Nectin-4/FAP Heterobivalent ProbeAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- eFAP-51, a novel FAPI dimer with enhanced tumor uptake and retention for theranostic applications.EJNMMI radiopharmacy and chemistry · 2026Article
- FAP-Targeted Radionuclide Therapy: Mechanisms, Clinical Applications, and Combination Strategies.Biomedicines · 2026Review
- FAPI Dimerization for Theranostic Applications: Molecular Design, Preclinical Validation, and Clinical Translation.Chemical & biomedical imaging · 2026Review
- Homomultimeric FAP Inhibitor-Based Radioligands for Cancer Theranostics: Design Principles, Structure-Function Relationships, and Preclinical Performance.Molecules (Basel, Switzerland) · 2026Review
- Safety and efficacy ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Review
- Short-chain fatty acids from gut microbiota restore Th17/Treg balance in rheumatoid arthritis: Mechanisms and therapeutic potential.Journal of translational autoimmunity · 2025Review
- A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein.EJNMMI research · 2025Article
- Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.International journal of molecular sciences · 2024Article
- [Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Fibroblast activation protein (FAP) has emerged as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. To exploit the therapeutic potential of suitably radiolabeled FAP inhibitors (FAPIs), this study presents the design and synthesis of a series of FAPI dimers to increase tumor uptake and retention. Preclinical evaluation and a pilot clinical PET imaging study were conducted to screen the lead compound with the potential for radionuclide therapy.
methodsThree new FAPI dimers were synthesized by linking two quinoline-based FAPIs with different spacers. The in vitro binding affinity and preclinical small animal PET imaging of the compounds were compared with their monomeric counterparts, FAPI-04 and FAPI-46. The lead compound, [
resultsThe three newly synthesized FAPI homodimers had high binding affinity and specificity in vitro and in vivo. Small animal PET imaging and biodistribution studies showed that [
conclusionDimerization is an effective strategy to produce FAPI derivatives with favorable tumor uptake, long tumor retention, and imaging contrast over its monomeric counterpart. We demonstrated that [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.